Cytarabine and daunorubicin (7 plus 3) regimen for remission induction of acute myelogenous leukemia

Hospital Pharmacy

Volumn 37, Issue 10, 2002, Pages 1044-1048

  Waddell, J Aubrey ^a   Solimando, Dominic A ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYTARABINE; DAUNORUBICIN; DIPHENHYDRAMINE; DOLASETRON MESILATE; GRANISETRON; METOCLOPRAMIDE; ONDANSETRON; PROCHLORPERAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SEROTONIN ANTAGONIST; THIETHYLPERAZINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; BACTERIAL INFECTION; BLEEDING; BRONCHOPNEUMONIA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; COLITIS; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG USE; FEVER; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LOBAR PNEUMONIA; LUNG EDEMA; MUCOSA INFLAMMATION; MYCOSIS; NAUSEA; RASH; REVIEW; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT INDICATION; VIRUS INFECTION; VOMITING;

EID: 0036801470     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870203701002     Document Type: Review

References (23)

1. National Comprehensive Cancer Network. NCCN acute myelogenous leukemia practice guidelines. The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM version]. Rockledge, PA: National Comprehensive Cancer Network; 2001.
2. Tallman MS. Therapy of acute myeloid leukemia. Cancer Control. 2001;8:62-78.
3. Rowe JM. What is the best induction regimen for acute myelogenous leukemia? Leukemia. 1998;12(suppl 1):S16-9.
4. Weil M, Glidewell OJ, Jacquillat C, et al. Daunorubicin in the therapy of acute granulocytic leukemia. Cancer Res. 1973;33:921-8.
5. Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: A useful agent in the treatment of acute leukemia in adults. Blood. 1968;32:507-23.
6. Yates JW, Wallace HJ, Ellison RR, et al. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57:485-8.
7. Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: A study by Cancer and Leukemia Group B. Blood. 1981;58:1203-12.
8. Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study. Blood. 1982;60:454-62.
9. Preisler H, Davis RB, Kirschner J, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B study. Blood. 1987;69:1441-9.
10. Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B. Blood. 1991;78:2520-6.
11. Arlin Z, Case DC, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia. 1990;4:177-83.
12. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study group study. J Clin Oncol. 1992;10:1103-11.
13. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15:103-9.
14. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm. 1999;56:729-64.
15. National Comprehensive Cancer Network. NCCN antiemesis practice guidelines. The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM version]. Rockledge, PA: National Comprehensive Cancer Network; 2001.
16. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17:2971-94.
17. Weiss RB. Hypersensitivity reactions. Semin Oncol. 1992;19:458-77.
18. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol. 2000;18:3558-85.
19. Mullin S, Beckwith MC, Tyler LS. Prevention and management of antineoplastic extravasation injury. Hosp Pharm. 2000;35:57-9,63-7,70-4.
20. Larson DL. Treatment of tissue extravasation by antitumor agents. Cancer. 1982;49:1796-9.
21. Larson DL. What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surgery. 1985;75:397-402.
22. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev. 1995;21:33-64.
23. King PD, Perry MC. Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin North Am. 1995;24:969-90.